Alan Martin

This inventor holds 10 USPTO granted patents and 17 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Arbutus Biopharma Corporation, Protiva Biotherapeutics, Inc.. Active years: 2013-2024.

USPTO Granted Patents = 10 (Patent Applications = 17)

% Patents Active = 70.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 3.8

ph-index = 6

Forward Citations = 279(Granted Patents)

Location History:

Burnaby, CA (2013)
Vancouver, CA (2014 - 2024)

Company Filing History:

6 out of 57

Arbutus Biopharma Corporation

patents

4 out of 46

Protiva Biotherapeutics, Inc.

patents

Years Active: 2013-2024

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12043833 - Targeted compositions (2024-07-23),

2. 11896672 - Targeted nucleic acid conjugate compositions (2024-02-13),

3. 11427823 - Targeted compositions (2022-08-30),

4. 11395854 - Trialkyl cationic lipids and methods of use thereof (2022-07-26),

5. 10561732 - Trialkyl cationic lipids and methods of use thereof (2020-02-18),

6. 10077232 - Cyclic cationic lipids and methods of use (2018-09-18),

7. 9352042 - Trialkyl cationic lipids and methods of use thereof (2016-05-31),

8. 9126966 - Cationic lipids and methods of use thereof (2015-09-08),

9. 8865675 - Compositions and methods for silencing apolipoprotein B (2014-10-21),

10. 8466122 - Trialkyl cationic lipids and methods of use thereof (2013-06-18),

Title: Innovations of Alan Martin in Targeted Therapeutics

Introduction

Alan Martin is a prominent inventor based in Vancouver, Canada. He has made significant contributions to the field of targeted therapeutics, particularly in the development of nucleic acid conjugates. With a total of 10 patents to his name, Martin's work focuses on innovative solutions for treating liver diseases.

Latest Patents

Among his latest patents, Martin has developed targeted compositions that provide certain nucleic acids, such as double-stranded siRNA molecules. These inventions include conjugates that comprise a targeting moiety, a double-stranded siRNA, and optional linking groups. The conjugates are designed to target therapeutic double-stranded siRNA to the liver, offering potential treatments for liver diseases, including hepatitis B and hepatitis D. Additionally, he has created targeted nucleic acid conjugate compositions that also include a targeting moiety and synthetic methods for preparing these conjugates.

Career Highlights

Throughout his career, Alan Martin has worked with notable companies in the biopharmaceutical sector. He has been associated with Arbutus Biopharma Corporation and Protiva Biotherapeutics, Inc., where he has contributed to the advancement of therapeutic technologies. His expertise in the field has positioned him as a key figure in the development of innovative treatments.

Collaborations

Martin has collaborated with esteemed colleagues, including James Heyes and Mark Wood. These partnerships have further enhanced his research and development efforts in targeted therapeutics.

Conclusion

Alan Martin's innovative work in the field of targeted therapeutics has the potential to significantly impact the treatment of liver diseases. His contributions through patents and collaborations highlight his dedication to advancing medical science.